KCNE3 (also known as MinK-related peptide 3 or MiRP2) is a potassium channel regulatory subunit that modulates the function of voltage-gated potassium channels, particularly KCNQ1 (also known as Kv7.1). The protein plays critical roles in regulating neuronal excitability, cardiac repolarization, and epithelial transport. KCNE3 is encoded by the KCNE3 gene located on chromosome 11.
KCNE3 is a member of the KCNE family (KCNE1-5), which are small single-pass membrane proteins that assemble with voltage-gated potassium channel α-subunits to form functional channels with diverse properties. Unlike KCNE1, which slows activation, KCNE3 accelerates activation and shifts the voltage dependence of channel opening.
| KCNE3 Protein |
|---|
| Protein Name | KCNE3 (MinK-Related Peptide 3) |
| Gene | [KCNE3](/genes/kcne3) |
| UniProt ID | [Q9NP86](https://www.uniprot.org/uniprot/Q9NP86) |
| Molecular Weight | 17.6 kDa |
| Subcellular Location | Plasma membrane |
| Protein Family | KCNE family (MinK-related peptides) |
| Gene Location | 11q13.4 |
KCNE3 contains a single transmembrane α-helix that anchors the protein in the plasma membrane. The extracellular N-terminal domain and intracellular C-terminal tail interact with the S4-S5 linker and C-terminal domain of KCNQ1 channels to modulate their gating properties. The protein forms disulfide bonds with channel β-subunits and undergoes post-translational modifications including glycosylation.
KCNE3 primarily assembles with KCNQ1 to form channels with distinct properties compared to KCNE1-containing channels. Key functions include:
- KCNQ1/KCNE3 channels: Generate slowly activating, non-inactivating currents that contribute to the M-current, a key regulator of neuronal excitability
- Voltage dependence: Shifts activation to more negative potentials, making channels more responsive at resting membrane potentials
- Kinetic properties: Accelerates activation kinetics compared to homomeric KCNQ1 channels
KCNE3 is expressed in:
- Brain: Hippocampus, cortex, and basal ganglia — regions affected in Alzheimer's and Parkinson's disease
- Heart: Cardiac ventricles where it contributes to repolarization
- Inner ear: Hair cells involved in auditory transduction
- Epithelial tissues: Kidney and intestine
In neurons, KCNQ1/KCNE3 channels regulate:
- Resting membrane potential stability
- Action potential threshold
- Spike frequency adaptation
- Synaptic integration
These channels are critical for preventing hyperexcitability and maintaining proper neuronal signaling.
Potassium channel dysfunction is increasingly recognized in Alzheimer's disease pathophysiology:
- Aβ toxicity: Amyloid-β peptides directly affect KCNQ1 channel function, disrupting neuronal excitability
- Calcium dysregulation: KCNE3-containing channels may contribute to calcium homeostasis through voltage control
- Network hyperexcitability: Loss of M-current function leads to cortical hyperexcitability observed in AD patients
- Therapeutic potential: SK channel activators (related potassium channels) are under investigation for AD treatment
Evidence for KCNE3 involvement in PD:
- Dopaminergic neuron survival: Potassium channels regulate dopaminergic neuron excitability and survival
- Motor control: KCNQ1/KCNE3 channels in the striatum modulate movement
- Mitochondrial function: Channel dysfunction may contribute to energy metabolism deficits
- Potential therapeutic target: Modulating neuronal excitability is a PD therapeutic strategy
- Motor neuron excitability: Potassium channels regulate motor neuron excitability; dysfunction may contribute to ALS pathogenesis
- Channel modulators under investigation: Research into potassium channel openers for ALS therapy continues
KCNE3 and related potassium channels represent potential therapeutic targets:
- Channel openers: Drugs that enhance KCNQ1/KCNE3 function could reduce neuronal hyperexcitability
- Selective modulators: Developing KCNE3-specific compounds remains a challenge
- Combination therapy: Targeting multiple potassium channel subtypes may provide benefits
KCNE3 mutations are associated with:
- Cardiac arrhythmias: Brugada syndrome and atrial fibrillation
- Sudden infant death syndrome: Channel dysfunction in cardiac tissue
- Gitelman syndrome: When combined with other channel mutations
- Preclinical stage: KCNE3-specific modulators are not yet in clinical trials
- Related targets: SK channels (KCNN1-4) are further along in development for neurodegenerative diseases
- Challenge: Developing subtype-selective KCNE modulators due to high similarity among KCNE proteins
- Natural compounds: Certain plant-derived compounds modulate KCNQ channels
- Repurposing potential: Existing potassium channel activators could be investigated for neurodegenerative applications